Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

Vaccine

Volumn 13, Issue 11, 1995, Pages 1006-1012

  Moldoveanu, Z ^a   Clements, M L ^b   Prince, S J ^a   Murphy, B R ^c   Mestecky, J ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antibody response; immunization; Influenza virus; secretory immunity

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VACCINATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ADULT; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NASAL MUCOSA; SALIVA; VACCINES, INACTIVATED;

EID: 0029162013     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00016-T     Document Type: Article

References (43)

1. Secretory anti-influenza immunity
2. Introduction to oral immunization against viral infections
3. Oral immunization and secretory immunity to viruses
4. Induction, persistence and strain specificity of haemagglutinin-specific secretory antibodies in lungs of mice after intragastric administration of inactivated influenza virus vaccines
5. The systemic and mucosal immune response of humans to influenza virus
6. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG
7. Neutralization of influenza virus by low concentrations of hemagglutinin-specific polymeric immunoglobulin A inhibits viral fusion activity, but activation of the ribonucleoprotein is also inhibited
8. The common mucosal immune system and current strategies for induction of immune responses in extemal secretions
9. In defense of mucosal surfaces: development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens
10. Overview of the mucosal immune system
11. A common mucosal immune system revisited
12. Migration of lymphocytes in the mucosal immune system
13. The mucosal immune system: from fundamental concepts to vaccine development
14. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response
15. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans
16. Antibodies secreting cells in the evaluation of the immunogenicity of oral vaccine
17. Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans
18. Indirect measurement of intestinal immune responses to an orally administered attenuated bacterial vaccine
19. Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens
20. Cellular origins of human polymeric and monomeric IgA: enumeration of single cells secreting polymeric gA1 and IgA2 in peripheral blood, bone marrow, spleen, gingiva and synovial tissue
21. Preliminary results of oral influenza vaccination with live attenuated viruses
22. Some problems of modern influenza prophylaxis with live vaccine
23. Secretory antibody following oral influenza immunization
24. Agedependent antibody response in mice and humans following oral influenza immunization
25. Immunogenicity and efficacy of orally administered inactivated influenza virus vaccine in mice
26. Efficacy of inactivated influenza vaccine delivered by oral administration
27. Oral immunization with influenza virus: experimental and clinical studies
28. Immune responses to influenza virus in orally and systemically immunized mice
29. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell rectivity
30. Mouse model for evaluation of protective mucosal immunity to influenza virus
31. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults
32. Modification of the method for the estimation of xylose in urine
33. Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers
34. A plastic intraoral device for the collection of human parotid saliva
35. Antibody-secreting cells
36. Assay of human IgA subclass antibodies in serum and secretions by means of monoclonal antibodies
37. Measurement of hemagglutination-inhibiting antibody to influenza virus in the 1976 influenza vaccine program: methods and test reproducibility
38. Oral immunization for the prevention of dental diseases
39. Secretory immunological response after intranasal inactivated influenza A virus vaccination: evidence for immunoglobulin A memory
40. Immunization of man and animals against influenza by oral and intranasal routes
41. Cells producing immunoglobulins and other immune factors in human nasal mucosa
42. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus
43. Targeting and controlled release of antigens for the effective induction of secretory antibody responses